RCKT vs. ADMA, ACLX, AKRO, RYTM, SRRK, IMVT, APLS, VKTX, ACAD, and CRNX
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include ADMA Biologics (ADMA), Arcellx (ACLX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs.
ADMA Biologics (NASDAQ:ADMA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
ADMA Biologics has a net margin of 17.80% compared to Rocket Pharmaceuticals' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Rocket Pharmaceuticals' return on equity.
ADMA Biologics currently has a consensus price target of $21.25, suggesting a potential upside of 34.15%. Rocket Pharmaceuticals has a consensus price target of $47.27, suggesting a potential upside of 351.51%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than ADMA Biologics.
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ADMA Biologics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics received 22 more outperform votes than Rocket Pharmaceuticals when rated by MarketBeat users. However, 73.22% of users gave Rocket Pharmaceuticals an outperform vote while only 72.08% of users gave ADMA Biologics an outperform vote.
ADMA Biologics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
In the previous week, ADMA Biologics had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for ADMA Biologics and 3 mentions for Rocket Pharmaceuticals. ADMA Biologics' average media sentiment score of 0.94 beat Rocket Pharmaceuticals' score of 0.45 indicating that ADMA Biologics is being referred to more favorably in the media.
Summary
ADMA Biologics beats Rocket Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 2/21/2025 by MarketBeat.com Staff
